Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

THURSDAY, Nov. 19, 2020 -- Among patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC), progression-free survival is significantly longer for those who receive first-line therapy with lorlatinib versus...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news